Abstract
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
Original language | English (US) |
---|---|
Pages (from-to) | 289-300 |
Number of pages | 12 |
Journal | Cell Stem Cell |
Volume | 4 |
Issue number | 4 |
DOIs | |
State | Published - Apr 3 2009 |
Externally published | Yes |
ASJC Scopus subject areas
- Cell Biology
- Molecular Medicine
- Genetics